The influence of concurrent treatment in H1975 cells, however, was quite unremarkable across all treatment regimens; and only nominally significant inhibitions were observed with sequential treatment schedules of 1 h with EGFR-TKI concentrations of 0.01, 0.1 and 10 μM.
← all excerpts
Piperlongumine in combination with EGFR tyrosine kinase inhibitors for the treatment of lung cancer cells.
1
—
—